Single-Patient trial aims to tackle obesity in rare bone disorder

NCT ID NCT07496463

ENROLLING_BY_INVITATION Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This phase 2 trial tests the drug setmelanotide in one person with pseudohypoparathyroidism type 1a (PHP1a), a rare genetic disorder that often causes severe obesity. The participant will receive daily injections of setmelanotide for six months to see if it leads to weight loss and improves metabolic health. The study is very early and small, so results will be preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Setmelanotide (a daily injection that targets the brain's appetite control pathway)
What this could lead to: If it works, this could point toward a treatment for obesity in people with pseudohypoparathyroidism type 1a, a rare genetic condition.
What could go wrong: This is a very early, single-patient study with no control group, so results may not apply to others. The drug may cause side effects like nausea or skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder pseudohypoparathyroidism pseudohypoparathyroidism type 1A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY PSEUDOHYPOPARATHYROIDISM TYPE 1A

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.